The first real clinical test of the cancer immunotherapy combination thesis has come back negative.

Incyte said Friday that its experimental drug epacadostat failed to improve the efficacy of Merck’s checkpoint inhibitor Keytruda when the two drugs were used together to treat patients with newly diagnosed melanoma.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • THANK GOD this episode of corporate mass hysteria is over. A drug that failed a monotherapy trial, only had single-arm add-on non-comparative data for itself (= nothing), and “pre-clinical efficacy” at 10x human doses in cherry-picked cell lines, has been rushed into God knows how many trials just for p-hacking purposes and hailed as the philosophical stone.

    I’m sorry for patients that such bogus projects are allowed to vacuum shareholder/taxpayer dollars, but since they are, the sooner these “experiments” are killed the better for biomedicine.

    Moral of the story : (1) pre-clinical and pharmacokinetics matter and (2) regulators should apply more Darwinian love to the pipeline.

  • Don’t discourage the keytruda method of cancer treatment keytruda is taking away all my squamous cancer in my face it has been a blessing to me

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy